Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia including social, psychological, physical and recreational aspects of daily living
Data highlight for.
U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets
AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective.
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Teva Pharmaceutical Industries Limited: New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY (risperidone) Extended-Release Injectable Suspension at SIRS 2024 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable formulation of risperidone microspheres
Additional UZEDY.